Form 4: Director Acquires BioCryst Stock for Retainer

Director Frank Steven acquired 1,262 shares of BioCryst Pharmaceuticals common stock valued at $8.91 per share as a substitute for his quarterly cash board member retainer.

Summary

• Director Frank Steven acquired 1,262 shares of BioCryst Pharmaceuticals common stock on May 29, 2026.
• The acquisition was made in lieu of 100% of the quarterly cash Board Member retainer, valued at $11,250.
• The shares were acquired at a price of $8.91 per share.
• Following this transaction, Mr. Steven beneficially owns 20,165 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details an insider transaction for compensation rather than providing performance metrics or strategic updates.

Positives

• Director compensation is being paid in equity, aligning director interests with shareholders.
• The transaction indicates continued board engagement and commitment to the company.

Negatives

• The filing does not provide information on the company's financial performance or strategic updates, making it difficult to assess the broader context of this transaction.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, especially when used for compensation, can signal confidence from management and directors in the company's future prospects. However, without broader financial or operational disclosures, the significance of this specific transaction remains limited.

Related Party Transactions

• Director Frank Steven received 1,262 shares of common stock in lieu of his quarterly cash Board Member retainer.

Stakeholder Impact

• Shareholders: The issuance of stock for compensation dilutes existing shareholders slightly, but also aligns director interests with long-term company performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Form 4, Insider Transaction, Director Compensation, Common Stock, Beneficial Ownership